Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948510 | 0.91 | NOTUM (0.64) | NOTUMHSD17B3LMNATHRBDRD2 | |
| SCHEMBL1948375 | 0.86 | DRD2 (0.51) | NOTUMHSD17B3LMNATHRBDRD2 | |
| SCHEMBL1948851 | 0.85 | NOTUM (0.44) | NOTUMHSD17B3LMNATHRBDRD2 | |
| SCHEMBL1950711 | 0.84 | DRD2 (0.48) | NOTUMHSD17B3LMNATHRBDRD2 | |
| SCHEMBL2641060 | 0.81 | LMNA (0.44) | NOTUMHSD17B3LMNATHRBDRD2 | |
| SCHEMBL14871648 | 0.80 | HSD17B3 (0.54) | NOTUMHSD17B3LMNAMAPTKDM4E | |
| SCHEMBL1950238 | 0.80 | TP53 (0.65) | NOTUMHSD17B3LMNAMAPTTP53 | |
| SCHEMBL5793078 | 0.79 | NOTUM (1.00) | NOTUMHSD17B3LMNADRD2DRD4 | |
| SCHEMBL5795715 | 0.79 | NOTUM (1.00) | NOTUMHSD17B3LMNADRD2DRD4 | |
| SCHEMBL5871063 | 0.78 | NOTUM (0.66) | NOTUMHSD17B3LMNADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | claimed |
| US-8426442-B2 | Compounds | XENTION LTD (GB) | 2013-04-23 | — | — | US | claimed |
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-8426442-B2 | Compounds | XENTION LTD (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20110136860-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136860-A1 | Compounds | NR3C2, NR5A1, NR0B2 | NOTUM 2101/4885HSD17B3 225/4885LMNA 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.